Noncoding RNA therapeutics—challenges and potential solutions
M Winkle, SM El-Daly, M Fabbri, GA Calin - Nature reviews Drug …, 2021 - nature.com
Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …
MicroRNA delivery through nanoparticles
MicroRNAs (miRNAs) are attracting a growing interest in the scientific community due to
their central role in the etiology of major diseases. On the other hand, nanoparticle carriers …
their central role in the etiology of major diseases. On the other hand, nanoparticle carriers …
A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
P Kumthekar, CH Ko, T Paunesku, K Dixit… - Science translational …, 2021 - science.org
Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of
the lack of precision therapies and limited therapeutic access to intracranial tumor sites due …
the lack of precision therapies and limited therapeutic access to intracranial tumor sites due …
Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment
Photothermal therapy (PTT), in which nanoparticles embedded within tumors generate heat
in response to exogenously applied laser light, has been well documented as an …
in response to exogenously applied laser light, has been well documented as an …
miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a
Background High frequency of recurrence is the major cause of the poor outcomes for
patients with hepatocellular carcinoma (HCC). microRNA (miR)-182-5p emerged as a high …
patients with hepatocellular carcinoma (HCC). microRNA (miR)-182-5p emerged as a high …
[HTML][HTML] Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation
AE Calvert, A Chalastanis, Y Wu, LA Hurley, FM Kouri… - Cell reports, 2017 - cell.com
Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and
IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and …
IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and …
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Glioblastoma ranks among the most lethal of all human cancers. Glioblastomas display
striking cellular heterogeneity, with stem-like glioblastoma stem cells (GSCs) at the apex …
striking cellular heterogeneity, with stem-like glioblastoma stem cells (GSCs) at the apex …
The new era of nanotechnology, an alternative to change cancer treatment
A Jurj, C Braicu, LA Pop, C Tomuleasa… - Drug design …, 2017 - Taylor & Francis
In the last few years, nanostructures have gained considerable interest for the safe delivery
of therapeutic agents. Several therapeutic approaches have been reported, such as …
of therapeutic agents. Several therapeutic approaches have been reported, such as …
Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis
Exosomes are nano-sized extracellular vesicles released by many cells that contain
molecules characteristic of their cell of origin, including microRNA. Exosomes released by …
molecules characteristic of their cell of origin, including microRNA. Exosomes released by …
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics
A Shea, V Harish, Z Afzal, J Chijioke, H Kedir… - Cancer …, 2016 - Wiley Online Library
Glioblastoma multiforme (GBM) is the most common and lethal cancer of the adult brain,
remaining incurable with a median survival time of only 15 months. In an effort to identify …
remaining incurable with a median survival time of only 15 months. In an effort to identify …